AMP PD / PDRD
Foundation for the National Institutes of Health
Advance your research into Parkinson's disease (PD) and related neurodegenerative disorders with the AMP® PDRD initiative. Building upon the foundational AMP® PD program, this expanded public-private partnership (managed by FNIH) integrates data to address PD and conditions with similar biology or symptoms (e.g., synucleinopathies, atypical Parkinsonisms). Access integrated, harmonized multi-omics and clinical data designed specifically to accelerate the discovery and validation of biomarkers that can differentiate these conditions, track progression, stratify patients, and ultimately improve clinical trial success and broaden treatment options across this spectrum of diseases.
Datasets
AMP PD / PDRD
Data Collection Time Frame
2018 - Present
Participants
Current: 10,908
Geographical Coverage
International
Usage Examples
Discovering and validating biomarkers capable of accurately differentiating Parkinson's disease from related synucleinopathies and atypical Parkinsonisms.
Identifying molecular signatures (using multi-omics) associated with specific disease subtypes, progression rates, or pathological features across this spectrum of disorders.
Understanding shared and distinct pathophysiological mechanisms between PD and related conditions.
Developing predictive models for disease diagnosis, prognosis, or patient stratification.
Informing the design of more efficient clinical trials by enabling better patient selection and identifying relevant endpoints.
Validating potential therapeutic targets across PD and related disorders.
Advancing precision medicine approaches by linking molecular profiles to clinical outcomes.
Data Modalities
Genomics
Whole Genome Sequencing (WGS)
Genotyping Arrays / WGG
Genetic Ancestry Data
Transcriptomics
Bulk RNA-Sequencing (RNA-Seq)
Single-Cell / Single-Nucleus RNA-Seq (sc/snRNA-Seq)
Proteomics
Targeted Proteomics
Untargeted Proteomics
Clinical Data
Clinical Assessments / Scales
Demographics
Medical History
Clinical Laboratory Tests
Biosamples (Source of Data)
Blood (incl. Plasma, Serum, PBMCs)
Cerebrospinal Fluid (CSF)
Postmortem Tissue (e.g., CNS)
Biomarkers (Specific analyte measurements)
[Coming soon] Fluid Biomarker Levels (e.g., Proteins like alpha-synuclein, Tau, Aβ)